Shares of pharma companies rallied up to 7% on Wednesday as strong earnings, a weakening rupee, and other supportive factors lifted investor sentiment, even as benchmark indices Sensex and Nifty traded in the red.
After opening lower, the Nifty Pharma index reversed losses and climbed nearly 1% to cross the 25,000 mark. The sectoral index also touched a fresh 52-week high of 25,043 during early trade before trimming some gains.
The Indian currency fell to 96.96 per dollar, breaching its all-time low of 96.6150 hit in the previous session. The currency is down 6% since the Iran war began in late February. A falling rupee is typically considered a positive for the export-heavy pharma sector.
Top pharma gainers today
fresh 52-week highAlong with the Q4 results, Zydus Lifesciences announced its biggest-ever share buyback worth Rs 1,100 crore via the tender route at a buyback price of Rs 1,150 per share, offering nearly a 13% premium over the stock’s previous closing price. Its board has also recommended a final dividend of Re 1 per share (100%) on a face value of Re 1 each, subject to shareholders’ approval at the company’s Annual General Meeting scheduled for August 11.
Mankind Pharma shares followed, surging over 3%. This comes after the company reported a 32% YoY rise in consolidated net profit to Rs 554 crore for the fourth quarter of the financial year 2026, from Rs 421 crore in the corresponding quarter of the previous financial year. The firm’s revenue from operations rose 12% YoY to Rs 3,443 crore during the quarter under review.
Laurus Labs, Aurobindo Pharma, and Biocon shares gained around 1% each, while those of Lupin, Sun Pharma, Cipla, Torrent Pharma, and Divi's Laboratories were trading in the green with marginal gains, as seen at 11 am. Bucking the trend, however, Ajanta Pharma, Piramal Pharma, Gland Pharma, Dr Reddy’s Labs, Abbot India, Glenmark, Alkem Labs, and IPCA Labs shares fell up to 1%.
What lies ahead?
“The index has been forming a clear higher-high, higher-low pattern, and the latest breakout keeps the medium-term trend in favour of buyers as long as it holds above the recent breakout zone. The immediate support now sits around 24,700 to 24,800, while a stronger cushion is visible near 24,400. A close below that band would weaken the breakout and indicate profit-booking rather than trend continuation,” according to Dasani.
The risk-reward remains favourable, but the entry point is no longer fresh after a sharp move, the analyst said. “The cleaner setup would come on controlled pullbacks rather than vertical rallies. The key confirmation from here is breadth. If participation remains broad across large pharma, domestic formulations and speciality businesses, the breakout could extend. If leadership narrows, the index may pause before attempting the next leg,” he added.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
